Key clinical point: Combination ado-trastuzumab emtansine (T-DM1) and neratinib appears more active than either agent alone.
Major finding: Among 19 response-evaluable patients, 12 patients (63%) had an objective response. Dose-limiting grade 3 diarrhea was observed in six patients.
Study details: A phase 1b study of 27 patients with HER2-positive metastatic breast cancer.
Disclosures: The study was funded by PUMA Biotechnology and the University of Pittsburgh. The authors reported financial affiliations with AstraZeneca, Eisai, Genentech, Guardant Health, Pfizer, Roche, Seattle Genetics, and several others.
Abraham J et al. J Clin Oncol. 2019 Aug 23. doi: 10.1200/JCO.19.00858.